Registry of Lobbyists
| Subject matters | Details | Categories |
|---|---|---|
|
Health
|
Communicating with government officials, in general, about policies and programs related to improving access for Canadian patients to effective treatments for common mental health, addiction and neuro-degenerative conditions.
|
Policies or Program
|
|
Health
|
Communicating with government officials, in general, about programs, reports, reviews and policies issued by or related to Canada's Drug Agency (formerly known as the Canadian Agency for Drugs and Technologies in Health).
|
Policies or Program
|
|
Health, Science and Technology
|
Communicating with government officials about data exclusivity, more specifically as it relates to the use of natural health products in biopharmaceutical preparations.
|
Policies or Program
|
|
Health, Labour
|
Communicating with government officials about federal healthcare benefits, including those delivered by members of the Federal Healthcare Partnership ("FHP"), such as the Department of National Defence, the Department of Indigenous Services, the Royal Canadian Mounted Police and the Department of Veterans Affairs.
|
Policies or Program
|
|
Health
|
Communicating with government officials about guidance, policies and documents issued by the Office of Patented Medicines and Liaison ("OPML") within the Office of Submissions and Intellectual Property, Therapeutic Products Directorate ("TPD").
|
Policies or Program
|
|
Health, Science and Technology
|
Communicating with government officials about initiatives, partnerships research and programs by the Canadian Institutes of Health Research ("CIHR").
|
Policies or Program
|
|
Health, Intellectual Property, International Trade
|
Communicating with government officials about international trade matters, including intellectual property provisions under the Canada-European Union Comprehensive Economic and Trade Agreement (“CETA”) and the Trans-Pacific Partnership (“TPP”).
|
Legislative Proposal, Bill or Resolution
|
|
Health, Intellectual Property
|
Communicating with government officials about regulations, guidelines reviews, references and reporting requirements issued by and/or related to the Patented Medicine Prices Review Board ("PMPRB").
|
Regulation
|
|
Health, Intellectual Property
|
Communicating with government officials about regulations related to patented medicines, including the Patented Medicines (Notice of Compliance) Regulations (SOR/93-133) under the Patent Act.
|
Regulation
|
|
Environment, Health
|
Communicating with government officials about regulations related to safe and environmentally-responsible disposal of biopharmaceutical compounds, including the Food and Drug Regulations (C.R.C., c. 870) under the Food and Drugs Act.
|
Policies or Program
|
|
Health
|
Communicating with government officials about the development of a national pharmacare program with the goal of (i) improving patient well-being and health outcomes and (ii) improving access to effective treatments for patients.
|
Policies or Program
|
|
Health, International Trade, Science and Technology
|
Communicating with government officials about the Food and Drugs Act, more specifically about (i) export restrictions, (ii) cross-border trade of biopharmaceuticals, (iii) approval, regulation and life-cycle management of therapeutic products and (iv) data protection.
|
Legislative Proposal, Bill or Resolution
|
|
Health
|
Communicating with government officials about the modernization and improvement of Health Canada's "Progressive Licensing Framework".
|
Policies or Program
|
|
Health, Intellectual Property
|
Communicating with government officials about the Patent Act, more specifically about the regulation of intellectual property for therapeutic products.
|
Legislative Proposal, Bill or Resolution
|
|
Health, Science and Technology, Taxation and Finance
|
Communicating with government officials about the Scientific Research and Experimental Development ("SR&ED") Tax Incentive Program, more specifically about investments in biopharmaceutical and health technology innovation.
|
Grant, Contribution or Other Financial Benefit
|
|
Health, Taxation and Finance
|
Communicating with government officials—including through the pan-Canadian Pharmaceutical Alliance (formerly known as the Pan-Canadian Pricing Alliance)—about drug pricing and reimbursement.
|
Policies or Program
|
Lundbeck Canada Inc. develops, manufactures and sells innovative biopharmaceutical products for the treatment of disorders originating in the central nervous system (CNS).
Michal Juul Sørensen, Vice-President & General Manager, Canada
Address:
2600 Alfred Nobel Boulevard
Suite 400
Ville Saint-Laurent, QC H4S 0A9
Canada
Telephone number:
514-844-8515
Fax number:
514-844-5495
Lundbeck Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking